Treatments that veterinarians
have hoped for

Specialty medicines
developed just for pets

Laverdia Bottles Dark

LAVERDIA-CA1

verdinexor

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-526.

This is not
chemotherapy

This is
cancer care
anywhere.

Shaping the future
of pet health

Investigational Treatment (GC376)

Feline Coronavirus FIP

Targeted Antiviral

Designed to block coronavirus from replicating

Rapid Reversal of Symptoms

In feline clinical trials

1st Investigational Therapy

For FIP shown to be safe and effective in published studies

Thanks to cats, we have a head start in the effort to develop an effective post-infection COVID-19 treatment for humans. Read more

Investigational Treatment (verdinexor)

Osteosarcoma

The most common bone tumor in dogs with average survival times of less than 6 months is after amputation.

Investigational Treatment (verdinexor)

Development Progress

Mid Stage

Our lead candidate has shown biologic activity against canine osteosarcoma (OS) cell lines at physiologically relevant doses and suggests that XPO1 inhibition alone or in combination with standard of care treatment following amputation offers promising potential for chemotherapeutic intervention in canine OS.

We are planning clinical trials in pet dogs to evaluate efficacy as we advance our strategy for regulatory approval.

Osteosarcoma

Targeted Formulation

Kills cancer cells while leaving normal cells unharmed

~40X Higher Incidence

In dogs than in human population

Pilot Studies

To be conducted in 2021

Development Milestones

Cell Line Studies

Conducted at Ohio State

Complete

Safety Study

In Development

Pilot Efficacy Studies

To be conducted in 2021

Planning

Investigational Treatment (eBAT)

Hemangiosarcoma

One of the more common cancers in dogs, accounting for approximately 20% of soft-tissue sarcomas and 5% of all non-skin tumors.

Investigational Treatment (eBAT)

Development Progress

Mid Stage

Our lead candidate is eBAT, a bispecific angiotoxin designed to specifically target hemangiosarcoma cells while reducing off target side effects.

Two studies with eBAT have demonstrated an increase in 6-month survival from <40% to approximately 70%. Further, 1 in 4 dogs were long term survivors, living more than 450 days after diagnosis.

Importantly, these studies also showed a single cycle of eBAT was as effective as repeated cycles with fewer adverse reactions.

Hemangiosarcoma

Development Milestones

FDA INAD File

Opened for eBAT

Complete

Safety and Dose Studies

ptimized dose

Complete

Pilot Field Efficacy Studies

Conducted Univ of Minnesota

Complete

Scaling Manufacturing

Capacity for CMC validation

Planning

Treatments. Vaccines.
Novel Applications.